MetaCap

Canton Strategic (CNTN) vs PDS Biotechnology (PDSB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

PDS Biotechnology (PDSB) has outperformed Canton Strategic (CNTN) over the past year, gaining 3.0% versus a loss of 50.6%. Canton Strategic is the larger company by market cap ($98.8 million vs $95.4 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CNTN-50.61%PDSB+2.97%
+134%+25%-83%
Nov 21, 20251 yearNov 20, 2026
CNTN-99.89%PDSB-88.60%
+103%-3%-110%
Jan 10, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CNTN versus PDSB key metrics
MetricCNTNPDSB
Share price$1.21$0.7774
Market cap$98.78M$95.39M
1-day change-1.63%-3.70%
YTD return-60.07%+0.96%
1-year return-50.61%+2.97%
5-year return—-92.46%
P/E ratio (TTM)20.17—
EPS (TTM)$0.06$-0.54
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-35.92M$-34.50M
52-week high$5.83$1.79
52-week low$1.19$0.195
Distance from 52-week high-79.25%-56.57%
Analyst consensus—strong_buy
Avg. price target upside—+478.85%
Average volume763.63K25.64M
Shares outstanding81.64M122.70M
Employees1221
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PDSB has outperformed CNTN by 53.6 percentage points over the past year.

About Canton Strategic

CNTN stock →

Canton Strategic Holdings, Inc. focuses on advancing institutional blockchain adoption and digitizing financial markets in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees

About PDS Biotechnology

PDSB stock →

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers.

Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees

CNTN vs PDSB FAQ

Which is bigger, Canton Strategic or PDS Biotechnology?

Canton Strategic (CNTN) is larger, with a market capitalization of $98.78M compared with $95.39M for PDS Biotechnology (PDSB).

Which stock has performed better over the past year, CNTN or PDSB?

PDSB returned +2.97% over the past 12 months, compared with -50.61% for CNTN (price return, excluding dividends). Past performance does not predict future results.

Are Canton Strategic and PDS Biotechnology in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons